<DOC>
	<DOCNO>NCT00486603</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , hydroxychloroquine temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving hydroxychloroquine together temozolomide radiation therapy may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose hydroxychloroquine give together radiation therapy temozolomide see well work treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Hydroxychloroquine , Radiation Therapy , Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose hydroxychloroquine administer combination radiotherapy temozolomide patient newly diagnose glioblastoma multiforme . ( Phase I ) - Assess toxicity regimen patient . ( Phase I ) - Determine overall survival patient treat regimen . ( Phase II ) Secondary - Assess frequency toxicity regimen patient . ( Phase II ) - Evaluate pharmacokinetics pharmacodynamics regimen patient . - Correlate average change autophagic vesicle baseline genotype , toxicity , clinical outcome . - Correlate presence TP53 PTEN gene BECN1 toxicity clinical outcome . OUTLINE : This multicenter , open-label , phase I , dose-escalation study hydroxychloroquine follow phase II study . - Phase I : - Initiation therapy : Patients receive oral temozolomide daily 6 week undergo conformal intensity-modulated radiotherapy 5 day week 6 week . Patients also receive oral hydroxychloroquine daily 10 week begin concurrently temozolomide radiotherapy . Cohorts 3-6 patient receive escalate dos hydroxychloroquine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Maintenance therapy : Beginning 28 day completion radiotherapy , patient receive oral temozolomide day 1-5 oral hydroxychloroquine day 1-28 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . Patients may continue receive hydroxychloroquine alone absence disease progression unacceptable toxicity . - Phase II : - Initiation therapy : Patients receive hydroxychloroquine MTD determine phase I , temozolomide , radiotherapy phase I . - Maintenance therapy : Patients receive hydroxychloroquine MTD determine phase I temozolomide phase I . Patients undergo blood tissue sample collection periodically pharmacological correlative study . Samples analyze mutational status TP53 PTEN gene copy number BECN1 via PCR ; change autophagy protein LC3 via gel electrophoresis ; difference formation LC3-II via immunoblotting . After completion study treatment , patient follow every 2 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm grade IV supratentorial astrocytoma ( glioblastoma multiforme ) Newly diagnose disease Diagnosis must make biopsy resection ≤ 3 month prior study entry PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 mg/dL Creatinine ≤ 2 time upper limit normal ( ULN ) ALT AST ≤ 4 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Mini Mental State Exam score ≥ 15 No concurrent psoriasis unless disease well control patient care specialist disorder agree monitor exacerbation No prior macular degeneration diabetic retinopathy No concurrent serious infection medical illness would preclude study therapy No malignancy within past 5 year except curatively treat carcinoma situ basal cell carcinoma skin No porphyria PRIOR CONCURRENT THERAPY : No prior radiotherapy , chemotherapy , immunotherapy , biologic agent ( e.g. , immunotoxins , immunoconjugates , antisense agent , peptide receptor antagonist , interferon , interleukin , tumorinfiltrating lymphocyte , lymphokineactivated killer cell therapy , gene therapy ) , hormonal therapy brain tumor No prior polifeprosan 20 carmustine implant ( Gliadel wafer ) GliaSite® brachytherapy No concurrent cytochrome P450 enzymeinducing anticonvulsant drug ( e.g. , phenytoin , carbamazepine , phenobarbital , primidone , oxcarbazepine ) No concurrent chemotherapeutic investigational agent cancer Concurrent glucocorticoid allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
</DOC>